Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan

While radium (Ra)-223 is among the multiple, known life-prolonging treatments in bone-predominant metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequencing has not been determined, particularly in the Asia-Pacific context. Hence, we aimed to compare treatment outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Ping-Chia, Chiang, Po-Hui, Chen, I-Hsuan Alan, Chen, Yen-Ta, Wang, Hung-Jen, Cheng, Yuan-Tso, Kang, Chih-Hsiung, Chen, Chien-Hsu, Liu, Yi-Yang, Su, Yu-Li, Chen, Yen-Hao, Luo, Hao-Lun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
7300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901946/
https://www.ncbi.nlm.nih.gov/pubmed/36749250
http://dx.doi.org/10.1097/MD.0000000000032671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901946/
https://www.ncbi.nlm.nih.gov/pubmed/36749250
http://dx.doi.org/10.1097/MD.0000000000032671

Ejemplares similares